Novo Tries New Japan Strategy To Boost Demand [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk ( NYSE:NVO is trying a different playbook in Japan, pushing to expand access to its weight-loss drugs by targeting patients willing to pay out of pocket. The idea is simple. Instead of waiting on broader insurance coverage, the company wants to work directly with doctors and patients to open up self-funded treatment pathways for GLP-1 drugs like Wegovy, which launched in Japan in February 2024. Management says demand is already there, but many patients are still shut out due to reimbursement limits. That creates a gap Novo is now trying to fill, especially as competition from Eli Lilly ( NYSE:LLY ) continues to build globally. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. The timing isn't random. Novo has been under pressure, with the stock down 48% in 2025 and another ~26% so far in 2026. Slower sales momentum, cheaper copycat drugs and underwhelming results from a next-gen obesity t
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026 [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- FDA approves new higher-dose version of Wegovy shots [BNN Bloomberg (Canada)]BNN Bloomberg
- FDA approves new higher-dose version of Wegovy shots [Yahoo! Finance Canada]Yahoo! Finance Canada
- FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share [CNBC]CNBC
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website